Objective:

To outline the EMA and FDA's joint guiding principles for good AI practice in drug development and regulatory alignment.

Approach:

Key Findings:

• The guiding principles are technology-neutral but emphasize the importance of execution and surrounding controls.
• AI applications must be mapped to risk with clear accountability and oversight.
• Lifecycle management is critical to ensure AI outputs remain reliable and trustworthy.

Interpretation:

Limitations:

• The principles do not introduce new requirements but serve as a reference for existing processes.
• The effectiveness of these principles depends on their implementation in practice.

Conclusion:

Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.